'김갑성' 기자의 전체기사
-
Akeso Announces Approval to Initiate Global Registrational T…
HONG KONG, Aug. 4, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezoliz
- 김갑성 기자
- 2025-08-04 13:56
-
CAS SciFinder integrates transformative new science-smart A…
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery COLUMBUS, Ohio, Aug. 4, 2025 -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the launch of the next evolution of CAS SciFinder®, the leading scientific search and insights platform. By integrating advanced AI—optimized for scientific applications—with the largest human-curated collection of global scientific knowledge, CAS SciFinder empowers researchers across R&D to work faster and unlock new opportuni
- 김갑성 기자
- 2025-08-04 12:01
-
CAS SciFinder, 혁신 과학지능형 AI 기능 통합으로 연구개발 효율성 제고 및 혁신 촉진
선도적인 솔루션으로 과학자에게 더 빠른 실행가능한 답변을 제공해 과학적 발견 가속화 콜럼버스, 오하이오 , 2025년 8월 4일 -- 미국화학회(American Chemical Society)의 과학 지식 관리 부문인 CAS가 과학검색•인사이트 플랫폼의 선두주자인 CAS SciFinder®의 차세대 버전 출시를 발표했다. CAS SciFinder는 과학 응용 분야에 최적화된 고급 AI를 사람이 엄선한 세계 최대 규모의 과학 지식 컬렉션과 통합해 연구자들이 더 빠르게 작업하고 새로운 혁신 기회를 발굴할 수 있도록 지원한다. 이는 CAS 솔루션 포트폴리오 사상 가장 중요한 AI 통합이다. 팀 발버그(Tim Wahlberg) CAS 최고제품책임자(CPO)는 "과학 정보는 너무도 다양하고 복잡해 일반적인 AI 도구가 정확히 해석하기 어렵다"면서 "CAS Content Collection™의 고품질 정형 데이터에 이러한 기술을 적용하고 당사의 과학자들을 통해 고급 AI 모델을 검증함으로써 과학자들이 신뢰할 수 있는 정확한 답변을 제공하는 과학지능형 AI 접근방식을 개발하는 데 성공했다"
- 김갑성 기자
- 2025-08-04 12:01
-
Alphamab Oncology Announces IND Application for Innovati…
SUZHOU, China, Aug. 4, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a first-in-human (FIH) clinical study of JSKN022 for the treatment of advanced malignant solid tumors. JSKN022 is an innovative bispecific ADC developed in-house with Alphamab's
- 김갑성 기자
- 2025-08-04 09:28
-
Alveolus Bio Secures Strategic Investment from Shilpa Medica…
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 -- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.&nb
- 김갑성 기자
- 2025-08-04 08:00
-
United Imaging Teases Multi-modality "Provider Success" Pro…
The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting in Las Vegas. HOUSTON, Aug. 4, 2025 -- United Imaging, a global manufacturer of modern medical imaging technology, will again be among the largest exhibitors at AHRA 2025 in Las Vegas, the Association for Medical Imaging Management, with a very hands-on, interactive display of new software and hardware technology. Building on examples of how it helps healthcare providers be successful, the company will showcase its breadth and scale across 85 countries (
- 김갑성 기자
- 2025-08-04 00:22
-
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma…
SHANGHAI, Aug. 3, 2025 -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NET), the dopamine transporter (DAT), and a gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), intended for the treatment of Major Depressive Disorder (MDD). MDD has a high prevalence rate, a high disability rate, and a high recurrence rate. In China, the lifetime prevalence
- 김갑성 기자
- 2025-08-03 18:23
-
Mabwell Announces IND Application Acceptance for CDH17-T…
SHANGHAI, Aug. 1, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA). 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: Ma
- 김갑성 기자
- 2025-08-01 22:00
-
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-
- 김갑성 기자
- 2025-08-01 21:02
-
Kazia Therapeutics Announces $2 Million Private Placemen…
SYDNEY, Aug. 1, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to an aggregate of approximately $2.0 million of ordinary shares and prefunded warrants. The securities being sold in the PIPE are priced at a 5% premium to the closing price of Kazia's ADSs on July 31, 2025. The PIPE is struc
- 김갑성 기자
- 2025-08-01 20:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
- IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 01시 40분